Results 201 to 210 of about 73,979 (245)

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky, Hidde M. Smits, Marlot van der Wal, Coco Dekkers, Celeste M. Boesjes, Julia Drylewicz, Marjolein de Bruin‐Weller, Femke van Wijk   +7 more
wiley   +1 more source

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Successful Management of Persistent DRESS with Tofacitinib: Two Case Reports

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marc Hernández‐Santacana, Ignasi Martí‐Martí, Victoria Amat‐Samaranch, Irene Fuertes de Vega, Priscila Giavedoni, José M. Mascaró Jr   +5 more
wiley   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

Postgraduate Medicine, 2013
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovsek
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Molecular cloning and functional characterization of duck Janus kinase 1

Molecular Immunology, 2020
Janus kinase 1 (JAK1) is a member of JAK family of non-receptor protein tyrosine kinases that plays critical roles in transducing cytokine signals via JAK-signal transducer and activator of transcription (STAT) signaling pathway. The importance of JAK1 in innate immunity has been well-studied in mammals and fish, yet in avian remains largely unknown ...
Dejian, Liu, Huijun, Zheng, Yaqian, Li, Peng, Zhou, Hui, Jin, Rui, Luo   +5 more
openaire   +2 more sources

Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide

Archives of Biochemistry and Biophysics, 2003
A high-affinity IL-2 receptor requires two Janus protein tyrosine kinases (JAKs) for IL-2 signal transduction: JAK1 and JAK3. Since transphosphorylation of the two kinases is presumed to occur after receptor engagement we examined the phosphorylation by recombinant JAK3 of a peptide substrate corresponding to the JAK1 activation loop (KAIETDKEYYTVKD ...
Ruixiu, Wang, Patrick R, Griffin, Eliza C, Small, James E, Thompson   +3 more
openaire   +2 more sources

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1

Bioorganic & Medicinal Chemistry Letters, 2013
The identification of a novel fused triazolo-pyrrolopyridine scaffold, optimized derivatives of which display nanomolar inhibition of Janus kinase 1, is described. Prototypical example 3 demonstrated lower cell potency shift, better permeability in cells and higher oral exposure in rat than the corresponding, previously reported, imidazo ...
Christopher A, Hurley, Wade S, Blair, Richard J, Bull, Christine, Chang, Peter H, Crackett, Gauri, Deshmukh, Hazel J, Dyke, Rina, Fong, Nico, Ghilardi, Paul, Gibbons, Peter R, Hewitt, Adam, Johnson, Tony, Johnson, Jane R, Kenny, Pawan Bir, Kohli, Janusz J, Kulagowski, Marya, Liimatta, Patrick J, Lupardus, Robert J, Maxey, Rohan, Mendonca, Raman, Narukulla, Rebecca, Pulk, Savita, Ubhayakar, Anne, van Abbema, Stuart I, Ward, Bohdan, Waszkowycz, Mark, Zak   +26 more
openaire   +2 more sources